IL-23 Inhibitors: Update on Safety and Dosing

Media formats available:

Ready to Claim Your Credits?

You have attempts to pass this post-test. Take your time and review carefully before submitting.

Good luck!

In The Pipeline: Phase 1, 2, and 3
In The Pipeline: Phase 1, 2, and 3
Psoriasis
In The Pipeline: Phase 1, 2, and 3
The Latest on Systemic Agents for Psoriasis: A Q&A With Jashin J. Wu, MD, FAAD
The Latest on Systemic Agents for Psoriasis: A Q&A With Jashin J. Wu, MD, FAAD
Psoriasis
The Latest on Systemic Agents for Psoriasis: A Q&A With Jashin J. Wu, MD, FAAD
- Jashin J. Wu, MD, FAAD
Annual Trends in Medicare Part D Prescription Claims for Guselkumab, 2018–2020
Annual Trends in Medicare Part D Prescription Claims for Guselkumab, 2018–2020
Psoriasis
Annual Trends in Medicare Part D Prescription Claims for Guselkumab, 2018–2020
- Jashin J. Wu, MD, FAAD
- Alexander Egeberg
- Priya Vedula Engel, MPH
- Sogol S. Javadi, BS
- Michael Korin
- Brandon Smith, BA
Verrucous Psoriasis
Verrucous Psoriasis
Psoriasis
Verrucous Psoriasis
- Maria Bao-Loc-Trung, BS
- George Jeha, MD
- Deborah Hilton, MD